Hyperuricemia Is an Independent Predictor of Contrast-Induced Acute Kidney Injury and Mortality in Patients Undergoing Percutaneous Coronary Intervention
Restricted accessResearch articleFirst published online September, 2015
Hyperuricemia Is an Independent Predictor of Contrast-Induced Acute Kidney Injury and Mortality in Patients Undergoing Percutaneous Coronary Intervention
We investigated whether hyperuricemia is an independent predictor of contrast-induced acute kidney injury (CI-AKI) and mortality in patients undergoing percutaneous coronary intervention (PCI). In a single-center study of 1772 patients undergoing PCI, the development of CI-AKI and mortality during a 2.8-year median follow-up period was assessed. The incidence of CI-AKI was significantly higher in the hyperuricemic group than in the normouricemic group (5.78% vs 1.76%, P < .001). According to multivariate analysis (after adjusting for potential confounding factors), hyperuricemia predicted CI-AKI (odds ratio: 1.962; 95% confidence interval [CI]: 1.014-3.798; P = .045). The other risk factors for CI-AKI were >75 years, emergent PCI, chronic kidney disease (CKD), and anemia. Hyperuricemia with a tendency toward significantly independently predicted long-term mortality, after adjusting for CI-AKI, CKD, and emergent PCI (hazard ratio: 1.571; 95% CI: 1.006-2.452; P = .047). In patients undergoing PCI, hyperuricemia is associated with a risk of CI-AKI. Furthermore, after adjusting for other variables, including CI-AKI and CKD, long-term mortality after PCI was higher in those with hyperuricemia than with normouricemia.
McCulloughPAAdamABeckerCR. Epidemiology and prognostic implications of contrast–induced nephropathy. Am J Cardiol. 2006;98
(8):5K–13K.
2.
AbeMMorimotoTAkaoM. Relation of contrast-induced nephropathy to long-term mortality after percutaneous coronary intervention. Am J Cardiol. 2014;114
(6A):362–368.
3.
LiuYTanNChenJ. The relationship between hyperuricemia and the risk of contrast-induced acute kidney injury after percutaneous coronary intervention in patients with relatively normal serum creatinine. Clinics (Sao Paulo). 2013;68
(1):19–25.
4.
ChungWKimAJRoHChangJHLeeHHJungJY. Hyperuricemia is an independent risk factor for mortality only if chronic kidney disease is present. Am J Nephrol. 2013;37
(5):452–461.
5.
SaritemurMTurkeliMKalkanKTanbogaIHAksakalE. Relation of uric acid and contrast–induced nephropathy in patients undergoing primary percutaneous coronary intervention in the ED. Am J Emerg Med. 2014;32
(2):119–123.
6.
OkinoSFukuzawaSInagakiM. Hyperuricemia as a risk factor for progressive renal insufficiency after coronary intervention in patients with chronic kidney disease. Cardiovasc Interv Ther. 2010;25
(2):105–111.
7.
FangJAldermanMH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. JAMA. 2000;283
(18):2404–2410.
8.
NiskanenLKLaaksonenDENyyssonenK. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med. 2004;164
(14):1546–5151.
9.
MoriarityJTFolsomARIribarrenCNietoFJRosamondWD. Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol. 2000;10
(3):136–143.
10.
StrasakARuttmannEBrantL. Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83,683 Austrian men. Clin Chem. 2008;54
(2):273–284.
11.
SpoonDBLermanARuleAD. The association of serum uric acid levels with outcomes following percutaneous coronary intervention. J Interv Cardiol. 2010;23
(3):277–283.
12.
MarenziGLauriGAssanelliE. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2004;44
(9):1780–1785.
13.
FilippatosGSAhmedMIGladdenJD. Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data. Eur Heart J. 2011;32
(6):712–720.
14.
MehranRAymongEDNikolskyE. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44
(7):1393–1399.
15.
ElbasanZŞahinDYGürM. Contrast-induced nephropathy in patients with ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Angiology. 2014;65
(1):37–42.
16.
ToprakOCiritMEsiEPostaciNYesilMBayataS. Hyperuricemia as a risk factor for contrast-induced nephropathy in patients with chronic kidney disease. Catheter Cardiovasc Interv. 2006;67
(2):227–235.
17.
LieseADHenseHWLowelHDoringATietzeMKeilU. Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. World Health Organization Monitoring Trends and Determinants in Cardiovascular Diseases. Epidemiology. 1999;10
(4):391–397.
18.
CulletonBFLarsonMGKannelWBLevyD. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999;131
(1):7–13.
19.
PaneroFGrudenGPerottoM. Uric acid is not an independent predictor of cardiovascular mortality in type 2 diabetes: a population-based study. Atherosclerosis. 2012;221
(1):183–188.
20.
LiuWCHungCCChenSC. Association of hyperuricemia with renal outcomes, cardiovascular disease, and mortality. Clin J Am Soc Nephrol. 2012;7
(4):541–548.
21.
NeriLRocca ReyLALentineKL. Joint association of hyperuricemia and reduced GFR on cardiovascular morbidity: a historical cohort study based on laboratory and claims data from a national insurance provider. Am J Kidney Diseases. 2011;58
(3):398–408.
22.
RudnickMFeldmanH. Contrast-induced nephropathy: what are the true clinical consequences?Clin J Am Soc Nephrol. 2008;3
(1):263–272.
23.
SarnakMJLeveyASSchoolwerthAC. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108
(17):2154–2169.
24.
SautinYYNakagawaTZharikovSJohnsonRJ. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol. 2007;293
(2):C584–C596.
25.
SchlotteVSevanianAHochsteinPWeithmannKU. Effect of uric acid and chemical analogues on oxidation of human low density lipoprotein in vitro. Free Radic Biol Med. 1998;25
(7):839–847.
26.
CorryDBEslamiPYamamotoKNybyMDMakinoHTuckML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin–angiotensin system. J Hypertens. 2008;26
(2):269–275.
27.
MazzaliMKanellisJHanL. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol. 2002;282
(6):F991–F997.
28.
KanellisJWatanabeSLiJH. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension. 2003;41
(6):1287–1293.
29.
KangDHParkSKLeeIKJohnsonRJ. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol. 2005;16
(12):3553–3562.
KanbayMYilmazMISonmezA. Serum uric acid level and endothelial dysfunction in patients with nondiabetic chronic kidney disease. Am J Nephrol. 2011;33
(4):298–304.
32.
BerryCEHareJM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol. 2004;555
(pt 3):589–606.
33.
MesserliFHFrohlichEDDreslinskiGRSuarezDHAristimunoGG. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med. 1980;93
(6):817–821.
34.
IsekiKOshiroSTozawaMIsekiCIkemiyaYTakishitaS. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res. 2001;24
(6):691–697.
